OBJECTIVE: The following comprehensive review describes the evolution of stimulant drug formulations used in the treatment of attention-deficit/hyperactivity disorder (ADHD). Emphasis is placed on the basic and clinical pharmacology of the dl-methylphenidate (MPH) transdermal system (MTS). METHODS: The pharmacokinetic and pharmacodynamic literature pertaining to MPH and amphetamine enantiomers was reviewed in the context of ADHD therapy and MTS as a treatment option. RESULTS: MTS incorporates MPH into an adhesive monolithic matrix, using the free base form of the drug to facilitate transdermal absorption. MTS technology minimizes contact dermatitis by eliminating to need for percutaneous penetration enhancers. After a lag time of approximately 2 h, plasma concentrations of the therapeutic d-MPH isomer become detectable, then continuously rise over the course of the recommended 9 h wear time. Concentrations of l-MPH typically attain 40-50% that of d-MPH (vs. 1-2% following oral MPH). Unauthorized MTS removal poses some misuse liability and over 50% of MTS drug content remains in the discarded system. CONCLUSIONS: While liquid or chewable MPH formulations overcome potential swallowing difficulties, as do sprinkled once-daily extended-release (ER) MPH products, only MTS addresses swallowing difficulties while also offering a flexible individualized MPH exposure time in a once-daily MPH regimen.
OBJECTIVE: The following comprehensive review describes the evolution of stimulant drug formulations used in the treatment of attention-deficit/hyperactivity disorder (ADHD). Emphasis is placed on the basic and clinical pharmacology of the dl-methylphenidate (MPH) transdermal system (MTS). METHODS: The pharmacokinetic and pharmacodynamic literature pertaining to MPH and amphetamine enantiomers was reviewed in the context of ADHD therapy and MTS as a treatment option. RESULTS:MTS incorporates MPH into an adhesive monolithic matrix, using the free base form of the drug to facilitate transdermal absorption. MTS technology minimizes contact dermatitis by eliminating to need for percutaneous penetration enhancers. After a lag time of approximately 2 h, plasma concentrations of the therapeutic d-MPH isomer become detectable, then continuously rise over the course of the recommended 9 h wear time. Concentrations of l-MPH typically attain 40-50% that of d-MPH (vs. 1-2% following oral MPH). Unauthorized MTS removal poses some misuse liability and over 50% of MTS drug content remains in the discarded system. CONCLUSIONS: While liquid or chewable MPH formulations overcome potential swallowing difficulties, as do sprinkled once-daily extended-release (ER) MPH products, only MTS addresses swallowing difficulties while also offering a flexible individualized MPH exposure time in a once-daily MPH regimen.
Authors: Mark Froimowitz; Yonghong Gu; Les A Dakin; Pamela M Nagafuji; Charles J Kelley; Damon Parrish; Jeffrey R Deschamps; Aaron Janowsky Journal: J Med Chem Date: 2007-01-25 Impact factor: 7.446
Authors: Jennifer Kim Penberthy; Daniel Cox; Marc Breton; Raina Robeva; M Layne Kalbfleisch; Tim Loboschefski; Boris Kovatchev Journal: Appl Psychophysiol Biofeedback Date: 2005-03
Authors: D Tuerck; Y Wang; M Maboudian; Y Wang; G Sedek; F Pommier; S Appel-Dingemanse Journal: Int J Clin Pharmacol Ther Date: 2007-12 Impact factor: 1.366
Authors: Ronald Steingard; Sarper Taskiran; Daniel F Connor; John S Markowitz; Mark A Stein Journal: J Child Adolesc Psychopharmacol Date: 2019-04-30 Impact factor: 2.576
Authors: William C Griffin; Andrew J Novak; Lawrence D Middaugh; Kennerly S Patrick Journal: Pharmacol Biochem Behav Date: 2010-02-01 Impact factor: 3.533
Authors: Hao-Jie Zhu; Kennerly S Patrick; Arthur B Straughn; Owen T Reeves; Hilary Bernstein; Jian Shi; Heather J Johnson; Joshua M Knight; Aaron T Smith; Robert J Malcolm; John S Markowitz Journal: J Clin Psychopharmacol Date: 2017-08 Impact factor: 3.153